Deerfield Beach, FL -- (SBWIRE) -- 01/09/2017 -- Pyrimethamine is an antiparasitic compound and used to treat serious parasite infection of the body, brain. It can be also utilized to prevent toxoplasmosis infection in individuals with HIV infection. Pyrimethamine possesses some tissue schizonticidal action against malaria parasites of humans. The combination of pyrimethamine with sulfadoxine is used prevent certain types of malaria. Pyrimethamine belongs to a category of drugs known as antiparasitics. However, the Centers for Disease Control and Prevention (CDC), no longer recommends consumption of pyrimethamine alone to prevent or treat malaria.

Increasing prevalence of toxoplasmosis coupled with high investment in R&D for toxoplasmosis is expected to propel the market growth in the years to come. Rising incidence of protozoan disease such as malaria in Asia Pacific region could further surge the market growth. Moreover, government initiatives and regulations expected to drive the market for pyrimethamine treatment market in the region over the forecast period. However, several side effects of higher doses of pyrimethamine such as abdominal cramps, nausea, vomiting, dry mouth, weight loss, and diarrhea may hamper market growth during the forecast period.

Get Sample Research Report at: http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=58510

The study provides a decisive view on the pyrimethamine treatment market by segmenting the market based on drug and geography. Based on drug, the pyrimethamine treatment market has been segmented into two drugs such as Daraprim and Fansidar. The Daraprim segment accounted for largest share of the pyrimethamine treatment market.

Geographically, the pyrimethamine treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa, further bifurcation of region on the country level, which include U.S., Germany, UK, France, China, Japan and India. North America has witnessed strong growth of pyrimethamine treatment market in recent past years on account of the rising health awareness and high incidences from foodborne illness in the region. Asia Pacific is another leading region for pyrimethamine treatment market and is expected to exhibit significant growth over the forecast period. Latin America is also expected to grow at moderate pace over the forecast period.

Browse the full report at http://www.syndicatemarketresearch.com/market-analysis/pyrimethamine-treatment-market-global-industry-perspective-comprehensive-analysis.html

The report provides comprehensive view on the pyrimethamine treatment market, in which study included a detailed competitive scenario and product portfolio of key vendors. The report analyzes the attractiveness of segments. Additionally, the study analyzes market competition and industry players using Porter's five forces analysis. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period.

The detailed description of players includes parameters such as company overview, financial overview, business and recent developments of the company. Some of the major in the global pyrimethamine treatment market include Turing Pharmaceuticals, Impax Laboratories, Inc., Pfizer, Inc. GlaxoSmithKline plc, and others.

This report segments the global pyrimethamine treatment market as follows:

Global Pyrimethamine Treatment Market: Drug Segment Analysis

Daraprim
Fansidar

Global Pyrimethamine Treatment Market: Regional Segment Analysis

North America
U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East & Africa

Contact US:
Joel John
3422 SW 15 Street,Suit #8138
Deerfield Beach,Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Email: sales@syndicatemarketresearch.com
Website: http://www.syndicatemarketresearch.com